GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...

Gilead Sciences has paused five clinical trials of its investigational HIV drugs GS-1720 and GS-4182 after the American medicines regulator raised safety concerns. The once-weekly oral regimen was ...

The U.S. FDA ordered a pause on clinical trials of a combination therapy for HIV. This won't affect the company's other HIV ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb , licensed an experimental drug and diagnostic agent for ...

Trump administration officials are expected to release more details on their plan to lower prescription drug prices in the ...

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.